Dopamine receptors (DARs) are involved in the etiology and/or therapy of a number of neuropsychiatric and endocrine disorders. For instance, all receptor-based antiparkinsonian drugs work via stimulating the D1 DAR subtype whereas all FDA-approved antipsychotic agents are antagonists of this receptor. Most drugs targeting the D1 DAR are problematic, however, either being less efficacious as desired or possessing limiting side effects, most of which are due to reactivity at other receptors. One approach towards improved receptor specificity is to identify allosteric ligands that bind to less conserved regions of the receptor and therefore have the potential to be much more selective. The goal of this project is to use high throughput screening approaches to identify and develop novel, highly selective small molecule allosteric modulators of the D1 DAR for use as in vitro and in vivo pharmacological tools and in proof-of-concept experiments in animal models of neuropsychiatric disease. There are three different types of allosteric modulators that we are seeking, two of which will stimulate or augment receptor signaling, allosteric agonists and potentiators, while the third, allosteric antagonists, will attenuate receptor signaling. The present primary screening assay measures compound antagonism after an EC80 addition of dopamine by tracking calcium flux in a force-coupled, inducible Hek293 Trex D1 cell line. Freshly passaged cells are plated in 1536 well black, clear bottom plates at a density of 4000 cells/well in 3 ul of complete media containing 1x tetracycline inducer. After an overnight incubation at 30 C in 5% CO2, cells are loaded with 2 ul of the no wash Calcium Assay Kit (ABD Bioquest) and incubated at room temperature for 30 to 90 minutes. Agonist read: A 10 cycle (1 second/cycle) baseline measurement is taken and then the FDSS online 1536 pintool delivers 23 nl of compound library (as well as dopamine controls) to the plate. The plate is measured for kinetically at 1 cycle/sec for 180 seconds.  Following the 180 second read, 1 ul of an EC80 (negative modulation assay) is delivered by an onboard pipette head. Measurements are taken kinetically for an additional 180 seconds.
bao:BAO_0000812 "488995" ; # "has summary assay" -> "488995"
bao:BAO_0000808 bao:BAO_0000031 ; # "has primary assay" -> "primary assay"
bao:BAO_0000205 bao:BAO_0000219 ; # "has assay format" -> "cell-based format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BAO_0000397 bao:BAO_0000748 ; # "has inducer" -> "Tetracycline" || bao:BAO_0003102 bao:BAO_00020133 ; # "has role" -> "inducer"
bao:BA0_0090012 bao:BAO_0000284 ; # "has participant" -> "G protein coupled receptor" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_0000649 ; # "is bioassay type of" -> "calcium redistribution assay"
bao:BAO_0000212 bao:BAO_0000126 ; # "has assay method" -> "molecular redistribution determination method"
bao:BAO_0000207 bao:BAO_0000363 ; # "has detection method" -> "fluorescence intensity"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "\"Ligands of D1 Dopamine Receptors, antagonists\"" ; # "screening campaign name" -> ""Ligands of D1 Dopamine Receptors, antagonists""
bao:BAO_0002853 "Antagonist of Human D 1 Dopamine Receptor: qHTS." ; # "has assay title" -> "Antagonist of Human D 1 Dopamine Receptor: qHTS."
bao:BAO_0002854 bao:BAO_0000010 ; # "has bioassay type" -> "functional"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
bao:BAO_0002863 bao:BAO_0000536 ; # "has concentration throughput" -> "single concentration"
bao:BAO_0000109 "25 degree celsius" ; # "has temperature value" -> "25 degree celsius"
bao:BAO_0002833 "180 second" ; # "has incubation time value" -> "180 second"
bao:BA0_0090012 bao:BAO_0000894 ; # "has participant" -> "Dopamine"
bao:BAO_0000740 bao:BAO_0000080 ; # "has assay control" -> "positive control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "David Sibley" ; # "material entity assay provider" -> "David Sibley" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000373 ; # "has assay phase characteristic" -> "heterogeneous phase"
bao:BAO_0002000 bao:BAO_0000894 ; # "has measured entity" -> "Dopamine" || bao:BAO_0003102 bao:BAO_00020138 ; # "has role" -> "potentiator"
bao:BA0_0090012 "D(1A) dopamine receptor" ; # "has participant" -> "D(1A) dopamine receptor"
bao:BAO_0002004 <http://purl.obolibrary.org/obo/CLO_0001230> ; # "has cell line" -> "293 cell"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_9606> ; # "has organism" -> "Homo sapiens"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P21728" ; # "uniprot ID" -> "P21728"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "9606" ; # "NCBI taxonomy ID" -> "9606"
bao:BAO_0002922 "\"No wash calcium assay kit buffer, AAT Bioquest\"" ; # "has assay medium" -> ""No wash calcium assay kit buffer, AAT Bioquest""
bao:BAO_0002922 bao:BAO_0000596 ; # "has assay medium" -> "assay medium"
bao:BAO_0000212 bao:BAO_0000246 ; # "has assay method" -> "stable transfection"
bao:BAO_0000550 "Expressing the human D1 receptor and tetracycline inducer (HEK293 Trex D1)" ; # "DNA construct" -> "Expressing the human D1 receptor and tetracycline inducer (HEK293 Trex D1)"
bao:BAO_0003105 "dopamine receptor D1" ; # "has function" -> "dopamine receptor D1"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "1812" ; # "construct gene ID" -> "1812"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BA0_0090012 bao:BAO_0000874 ; # "has participant" -> "Calcium"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BAO_0000308 bao:BAO_0000908 ; # "has assay kit" -> "Fluo-8 No Wash Calcium Assay Kit"
bao:BAO_0000308 bao:BAO_0000248 ; # "has assay kit" -> "assay Kit"
bao:BAO_0000737 bao:BAO_0000832 ; # "has manufacturer" -> "ABD Bioquest" || bao:BAO_0003102 bao:BAO_0002626 ; # "has role" -> "biologics and screening manufacturer"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0000903 ; # "uses detection instrument" -> "FDSS6000"
bao:BAO_0000737 bao:BAO_0000935 ; # "has manufacturer" -> "Hamamatsu" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0000337 bao:BAO_0000200 ; # "has percent response" -> "percent activation"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has concentration unit" -> "percent"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "1" ; # "PubChem TID" -> "1"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002666 "10" ; # "has concentration value" -> "10"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
bao:BAO_0002787 "1" ; # "has concentration-point number" -> "1"
bao:BAO_0002845 "1" ; # "has repetition point-number" -> "1"
bao:BAO_0000196 bao:BAO_0000091 ; # "has mode of action" -> "inhibition"
bao:BAO_0002864 bao:BAO_0000136 ; # "has repetition throughput" -> "single repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "mp" ; # "Annotated by" -> "mp"
